allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes

Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes are genetically engineered donor-derived (allogeneic) T cells that express a chimeric antigen receptor (CAR) targeting CD123, the alpha subunit of the interleukin-3 receptor, which is overexpressed on leukemic stem cells and blasts in acute myeloid leukemia (AML). The CAR construct includes co-stimulatory domains from CD28 and a signaling domain from CD3 zeta to enhance activation and persistence. Additionally, these cells express a truncated epidermal growth factor receptor (EGFRt), which serves as both a tracking marker and an inducible safety switch—allowing for selective elimination of the modified T cells if needed by administration of cetuximab. This therapy is being developed as an off-the-shelf immunotherapy for relapsed or refractory AML[1][6][7].